Comment from US Chamber of Commerce

Summary: The U.S. Chamber of Commerce supports the FDA's initiative to expand drug repurposing to address unmet medical needs. They argue that the private sector requires clear regulatory pathways, modernized intellectual property and exclusivity incentives, and flexible clinical trial designs to make repurposing research commercially viable and rewarding.